🇺🇸 FDA
Pipeline program

NERATINIB, Sindiar 2 mg cápsulas duras

GEICAM/2018-06

Phase 2 small_molecule active

Quick answer

NERATINIB, Sindiar 2 mg cápsulas duras for HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer. is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Breast Cancer.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials